Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD

ABP 959 is being developed as a biosimilar to Soliris® (eculizumab) reference product (RP), which was approved under orphan designation for a group of rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), an...

Descripción completa

Detalles Bibliográficos
Autores principales: McBride, Helen J., Frazer-Abel, Ashley, Thiemann, Sandra, Lehto, Sonya G., Hutterer, Katariina M., Liu, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640484/
https://www.ncbi.nlm.nih.gov/pubmed/37817009
http://dx.doi.org/10.1007/s00277-023-05439-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640484/
https://www.ncbi.nlm.nih.gov/pubmed/37817009
http://dx.doi.org/10.1007/s00277-023-05439-4

Ejemplares similares